Table 2.
Univariate and multivariate logistic regression analysis for different variables predicting pathological outcomes in the training cohort
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | p value | OR | 95% CI | p value | |
| Age, years | ||||||
| ≤ 45 | 1 | 1 | ||||
| > 45 | 0.412 | 0.158–1.070 | 0.044 | 0.191 | 0.053–0.680 | 0.011 |
| Hemoglobin, g/L | ||||||
| ≤ 110 | 1 | |||||
| > 110 | 0.730 | 0.170–3.124 | 0.671 | |||
| BMI, kg/m2 | ||||||
| ≥ 25 | 1 | |||||
| < 25 | 1.376 | 0.540–3.506 | 0.504 | |||
| Multifocality | ||||||
| Unifocal | 1 | |||||
| Multifocal | 0.538 | 0.206–1.408 | 0.207 | |||
| Menopausal status | ||||||
| Premenopausal | 1 | |||||
| Postmenopausal | 0.565 | 0.242–1.319 | 0.187 | |||
| Local invasion | ||||||
| No | 1 | |||||
| Yes | 0.867 | 0.645–5.575 | 0.246 | |||
| LVI | ||||||
| Present | 1 | 1 | ||||
| Absent | 1.897 | 1.697–3.963 | 0.026 | 3.970 | 2.355–8.382 | 0.045 |
| Clinical tumor size | ||||||
| T1 | 1 | |||||
| T2 | 0.871 | 0.219–3.472 | 0.594 | |||
| T3 | 0.450 | 0.086–2.349 | 0.250 | |||
| Lymph node status | ||||||
| N0 | 1 | |||||
| N1-2 | 1.202 | 0.500–2.892 | 0.681 | |||
| Histological grade | ||||||
| I–II | 1 | |||||
| III | 1.501 | 0.636–3.540 | 0.353 | |||
| Histological type | ||||||
| Others | 1 | – | ||||
| IDC | 0.881 | 0.168–4.626 | 0.881 | |||
| Progesterone receptor | ||||||
| Negative | 1 | – | ||||
| Positive | 0.433 | 0.182–1.034 | 0.059 | |||
| Estrogen receptor | – | – | ||||
| Negative | 1 | 1 | ||||
| Positive | 0.286 | 0.116–0.703 | 0.006 | 0.093 | 0.026–0.334 | 0.000 |
| Hormone receptor | ||||||
| Negative | 1 | |||||
| Positive | 0.301 | 0.122–0.739 | 0.009 | |||
| HER2 | ||||||
| Negative | 1 | 1 | ||||
| Positive | 1.743 | 0.743–4.088 | 0.201 | 3.569 | 1.142–11.151 | 0.029 |
| Ki67 | – | – | ||||
| ≤ 30 | 1 | – | ||||
| > 30 | 0.776 | 0.265–2.271 | 0.644 | |||
| Biological subtype | – | – | ||||
| HER2-enriched | 1 | – | ||||
| Luminal B | 0.333 | 0.121–0.915 | 0.016 | |||
| Triple-negative | 1.042 | 0.352–3.088 | 0.233 | |||
| NCT regimen | – | – | ||||
| TEC | 1 | |||||
| TCbH | 1.577 | 0.673–3.696 | 0.295 | |||
| NCT times | – | – | ||||
| > 4 | 1 | – | 1 | |||
| ≤ 4 | 0.187 | 0.070–0.498 | 0.001 | 0.060 | 0.014–0.250 | 0.000 |
OR odds ratio, CI confidence interval, BMI body mass index, HER2 human epidermal growth factor receptor 2, LVI lymphovascular invasion, NCT neoadjuvant chemotherapy, TEC docetaxel + epirubicin + cyclophosphamide, TCbH docetaxel + carboplatin + trastuzumab, IDC intraductal carcinoma